华蟾素注射液联合多西他及赛卡铂治疗晚期非小细胞肺癌的临床观察
发布时间：2019-05-26 21:05
【摘要】：目的观察华蟾素注射液联合多西他赛及卡铂方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法将98例晚期NSCLC患者分为观察组(49例)和对照组(49例),所有患者均接受多西他赛+卡铂方案(第1天多西他赛60mg/m~2静脉输液,第2天卡铂注射液300mg/m~2静脉输液全身化疗,3周为1个疗程,共4~6个疗程,观察组化疗同时在第1~14天联合使用华蟾素注射液20mL/d;评价患者治疗后的疗效、生存质量及不良反应。结果经4个疗程治疗后,观察组总缓解率(ORR)34.69%,疾病控制率(DCR)69.39%,对照组ORR 20.41%,DCR 34.69%,观察组ORR及DCR显著高于对照组(P0.05);观察组无进展生存期(PFS)为(6.5±1.2)个月,对照组为(2.9±1.1)个月,两组比较差异有统计学意义(P0.05);两组患者主要不良反应均较轻,患者均可耐受。结论晚期NSCLC患者应用华蟾素联合多西他赛卡铂化疗后能够控制病情进展,延长PFS,改善患者生活质量,且不良反应小,耐受性良好。
[Abstract]:Objective to observe the clinical efficacy and safety of cinobufagin injection combined with docetaxel and carboplatinum regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 98 patients with advanced NSCLC were divided into observation group (49 cases) and control group (49 cases). All patients received docetaxel 60mg/m~2 intravenous infusion on the first day. On the second day, carboplatin injection 300mg/m~2 intravenous infusion systemic chemotherapy, 3 weeks as a course of treatment, a total of 4 courses of treatment, the observation group chemotherapy at the same time on the 1st to 14th day combined use of cinobufagin injection 20 mL d; To evaluate the curative effect, quality of life and adverse reactions after treatment. Results after four courses of treatment, the total remission rate of (ORR) was 34.69%, the disease control rate of (DCR) was 6939%, the ORR of control group was 20.41%, and the ORR of control group was 34.69%. The ORR and DCR of observation group were significantly higher than those of control group (P 0.05). The non-progressive survival time of the observation group was (6.5 卤1.2) months, and that of the control group was (2.9 卤1.1) months, there was significant difference between the two groups (P 0.05). The main adverse reactions of the two groups were mild and tolerable. Conclusion cinobufagin combined with docetaxel chemotherapy in patients with advanced NSCLC can control the progress of the disease and prolong PFS, to improve the quality of life of patients with low adverse reactions and good tolerance.
【作者单位】： 山东省东营市东营区人民医院药剂科;山东省东营市东营区新区医院检验科;山东省东营市东营区人民医院老年科;山东省东营市东营区人民医院儿科;
【分类号】：R734.2
[Abstract]:Objective to observe the clinical efficacy and safety of cinobufagin injection combined with docetaxel and carboplatinum regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 98 patients with advanced NSCLC were divided into observation group (49 cases) and control group (49 cases). All patients received docetaxel 60mg/m~2 intravenous infusion on the first day. On the second day, carboplatin injection 300mg/m~2 intravenous infusion systemic chemotherapy, 3 weeks as a course of treatment, a total of 4 courses of treatment, the observation group chemotherapy at the same time on the 1st to 14th day combined use of cinobufagin injection 20 mL d; To evaluate the curative effect, quality of life and adverse reactions after treatment. Results after four courses of treatment, the total remission rate of (ORR) was 34.69%, the disease control rate of (DCR) was 6939%, the ORR of control group was 20.41%, and the ORR of control group was 34.69%. The ORR and DCR of observation group were significantly higher than those of control group (P 0.05). The non-progressive survival time of the observation group was (6.5 卤1.2) months, and that of the control group was (2.9 卤1.1) months, there was significant difference between the two groups (P 0.05). The main adverse reactions of the two groups were mild and tolerable. Conclusion cinobufagin combined with docetaxel chemotherapy in patients with advanced NSCLC can control the progress of the disease and prolong PFS, to improve the quality of life of patients with low adverse reactions and good tolerance.
【作者单位】： 山东省东营市东营区人民医院药剂科;山东省东营市东营区新区医院检验科;山东省东营市东营区人民医院老年科;山东省东营市东营区人民医院儿科;
【分类号】：R734.2
【相似文献】
相关期刊论文 前10条
1 陈秀珍;华蟾素注射液治疗晚期肿瘤300例[J];中国中医药信息杂志;2005年02期
2 邱炳力;董桂兰;;华蟾素注射液治疗晚期恶性肿瘤60例临床分析[J];中国当代医药;2010年32期
3 吕福鸣,孙清河,王慧娟,李新建;华蟾素注射液对豚鼠皮试刺激试验的影响[J];新乡医学院学报;2002年05期
4 陈燕平,刘秀娟;华蟾素注射液配合化疗治疗晚期恶性肿瘤临床观察[J];实用中西医结合临床;2003年02期
5 邓春美,兰海涛,张明,杨兰,白顺艳,刘秀宏;大剂量华蟾素治疗恶性肿瘤32例疗效观察[J];成都医药;2003年06期
6 陈U，
本文编号：2485631
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2485631.html
